Kisspeptin for IVF: Reducing Ovarian Hyperstimulation
Fertility Peptides and Biomarkers
0 OHSS cases
In a phase 2 trial of 60 women at high risk of ovarian hyperstimulation, kisspeptin-54 triggered oocyte maturation in 95% of patients with zero cases of moderate, severe, or critical OHSS.
Abbara et al., JCEM, 2015
Abbara et al., JCEM, 2015
View as imageOvarian hyperstimulation syndrome (OHSS) remains one of the most dangerous complications in fertility treatment. In severe cases, it hospitalizes patients with ascites, blood clots, and organ failure. The standard trigger for final oocyte maturation during IVF, human chorionic gonadotropin (hCG), directly stimulates the ovaries and is the primary cause of OHSS. Kisspeptin-54, a hypothalamic neuropeptide, offers a fundamentally different approach: rather than acting directly on the ovaries, it stimulates the brain's own GnRH release, producing a physiological LH surge calibrated by each patient's endogenous hormone reserves.[1] Phase 2 trial data shows this approach can trigger oocyte maturation with zero OHSS cases in high-risk women. This article is part of a broader look at AMH: the peptide biomarker for fertility.
Key Takeaways
- In a phase 2 trial of 60 high-risk women, kisspeptin-54 triggered oocyte maturation in 95% with zero cases of moderate, severe, or critical OHSS (Abbara et al., 2015)
- A second dose of kisspeptin-54 at 10 hours after the first improved oocyte yield in a follow-up phase 2 RCT (Abbara et al., 2017)
- Median ovarian volume was 44 ml with kisspeptin versus 73 ml with GnRH agonist and 138 ml with hCG trigger (Abbara et al., 2018)
- Abdominal pain was 13-fold less likely with kisspeptin than hCG, and abdominal bloating was 30-fold less likely (Abbara et al., 2018)
- Kisspeptin works by stimulating endogenous GnRH release, producing a self-limiting LH surge that prevents excessive ovarian stimulation (Thomsen and Humaidan, 2015)
- The kisspeptin trigger remains in phase 2 development and has not yet been compared to standard triggers in large phase 3 registration trials
Why OHSS Happens and Why Standard Triggers Cause It
IVF requires controlled ovarian stimulation to produce multiple mature eggs. Gonadotropin injections (FSH, sometimes with LH) drive the growth of multiple follicles over 10-14 days. When follicles reach target size, a "trigger" injection induces final oocyte maturation so eggs can be retrieved 34-36 hours later.
The conventional trigger, hCG, mimics the natural LH surge but with a critical difference: hCG has a much longer half-life than LH (roughly 24-36 hours versus 60 minutes). This prolonged ovarian stimulation drives continued follicular growth, fluid shifts, and angiogenesis, which in susceptible women spirals into OHSS. Thomsen and Humaidan reviewed the evolution of OHSS management and identified hCG as "the primary cause" of the syndrome.[2]
GnRH agonist triggers were developed as an alternative, stimulating the pituitary to release its own endogenous LH rather than injecting exogenous hCG. This substantially reduced OHSS risk, but at a cost: pregnancy rates were lower due to insufficient luteal phase support from the shorter LH surge.[2]
Kisspeptin offers a third option that acts even higher in the hormonal cascade.
How Kisspeptin Triggers Oocyte Maturation
Kisspeptin is the primary stimulator of GnRH neurons in the hypothalamus. When administered exogenously, kisspeptin-54 (the 54-amino-acid active form) stimulates the release of endogenous GnRH, which in turn triggers a pituitary LH surge. The key distinction: the magnitude of the LH surge depends on each patient's own GnRH and gonadotropin reserves rather than an externally imposed dose.[3]
This creates an inherent safety mechanism. Women with highly stimulated ovaries (the ones most at risk for OHSS) tend to have suppressed GnRH stores due to elevated estradiol negative feedback. Kisspeptin can only release what is there. In contrast, hCG bypasses this feedback entirely, stimulating ovarian LH receptors regardless of how many follicles are present.
Kasum et al. described kisspeptin as a "promising oocyte maturation trigger" specifically because of this physiological self-limiting mechanism, which should "prevent excessive stimulation of the ovaries."[1]
Mills and Dhillo reviewed the broader therapeutic translation of kisspeptin biology and highlighted its IVF application as one of the most advanced clinical programs, noting that kisspeptin administration "stimulates physiological reproductive hormone secretion" in both healthy individuals and those with reproductive disorders.[3]
The Phase 2 Trial Evidence
Abbara et al. 2015: First Proof of Concept
The landmark trial was a phase 2, multi-dose, open-label, randomized study conducted at Hammersmith Hospital IVF unit in London. Sixty women at high risk of developing OHSS were randomized to different subcutaneous doses of kisspeptin-54 to trigger oocyte maturation.[4]
Results:
- Oocyte maturation occurred in 95% of women
- Zero women developed moderate, severe, or critical OHSS
- The treatment induced an LH surge of approximately 12-14 hours duration
- Pregnancy rates were achieved, though the study was powered for safety rather than efficacy comparison
This was the first demonstration that kisspeptin-54 could safely trigger final oocyte maturation in the highest-risk IVF population, the group most likely to develop life-threatening OHSS. The trial used multiple dose levels (1.6, 6.4, 12.8, and 25.6 nmol/kg) administered subcutaneously, with the highest dose producing the most reliable oocyte maturation rates.
Abbara et al. 2017: Optimizing the Protocol
A follow-up phase 2 randomized controlled trial addressed a limitation of the first study: the kisspeptin-induced LH surge was shorter than the hCG-induced surge, which might yield fewer mature oocytes. The solution was a second dose of kisspeptin-54 administered 10 hours after the first.[5]
In 62 women at high risk of OHSS, the two-dose protocol improved oocyte yield compared to a single dose while maintaining the safety profile. The study confirmed that extending LH exposure through a second kisspeptin dose, rather than switching to hCG, preserved the OHSS-protective advantage.
Abbara et al. 2018: Head-to-Head Comparison
The most informative safety data came from a retrospective comparison of clinical parameters following three different triggers: hCG, GnRH agonist, and kisspeptin-54.[6]
The differences were stark:
| Parameter | hCG | GnRH Agonist | Kisspeptin |
|---|---|---|---|
| Median ovarian volume (2-6 days post-retrieval) | 138 ml | 73 ml | 44 ml |
| Abdominal pain risk (vs kisspeptin) | 13-fold higher | 2-fold higher | reference |
| Abdominal bloating risk (vs kisspeptin) | 30-fold higher | 4-fold higher | reference |
These numbers illustrate kisspeptin's advantage even over GnRH agonist trigger, which was already considered the standard OHSS-prevention strategy. Ovarian volume at 44 ml after kisspeptin versus 138 ml after hCG reflects a fundamentally different ovarian response to the two triggers.
Where Kisspeptin Fits in the IVF Trigger Hierarchy
The choice of trigger in IVF involves balancing OHSS risk against pregnancy outcomes. Each option occupies a different position on this spectrum.
hCG trigger: Highest OHSS risk but best-established pregnancy rates. Remains the standard for low-risk patients with normal ovarian response. The long half-life of hCG provides robust luteal support.
GnRH agonist trigger: Substantially reduced OHSS risk. Now widely used in high-responder protocols and donor egg cycles. Requires intensive luteal support (progesterone and sometimes estradiol) to compensate for the shorter LH surge. Pregnancy rates are comparable to hCG when freeze-all strategies are used.
Kisspeptin-54 trigger: Lowest OHSS risk based on phase 2 data. The most physiological approach, working through the patient's own GnRH-LH axis. The shorter LH surge (12-14 hours with single dose, extended with two-dose protocol) is both its safety advantage and its main limitation.
The practical question is whether kisspeptin's superior OHSS safety profile translates to better overall outcomes than GnRH agonist trigger, which is already quite safe. The answer requires phase 3 trials that have not yet been completed.
Understanding the Kisspeptin-Induced LH Surge
The pharmacology of kisspeptin's LH surge differs from both hCG and GnRH agonist triggers in ways that matter clinically.
When kisspeptin-54 is injected subcutaneously, it reaches the hypothalamus and binds to KISS1R receptors on GnRH neurons. This stimulates a burst of endogenous GnRH release from hypothalamic nerve terminals into the portal blood supply connecting the hypothalamus to the pituitary. The pituitary then releases its stored LH in response, creating the surge needed for oocyte maturation.
The first Abbara et al. trial found that a single kisspeptin-54 dose produced an LH surge lasting approximately 12-14 hours.[4] For comparison, hCG maintains LH-like activity for 24-36 hours, and a GnRH agonist trigger produces a surge of roughly 24-36 hours through a different mechanism (pituitary flare). The shorter kisspeptin surge was sufficient for oocyte maturation (95% rate) but raised concerns about whether embryo quality and pregnancy rates might be affected.
The two-dose protocol addressed this directly. By giving a second kisspeptin-54 injection 10 hours after the first, the duration of LH exposure was extended without resorting to hCG supplementation. Abbara et al. showed this improved oocyte yield while preserving the OHSS-free safety record.[5]
The self-limiting nature of the kisspeptin surge is what prevents OHSS. Once the hypothalamic GnRH stores are released, kisspeptin cannot generate additional GnRH until those stores replenish. In highly stimulated women with many follicles, elevated estradiol levels actually suppress GnRH reserves through negative feedback, meaning the kisspeptin surge is proportionally smaller in the very women who are at highest OHSS risk. This is the opposite of hCG, where the exogenous hormone acts on every ovarian LH receptor regardless of how many follicles are present.
The clinical implication is that kisspeptin trigger may be especially suited for freeze-all cycles, where all embryos are cryopreserved and transferred in a subsequent unstimulated cycle. Freeze-all eliminates the need for robust luteal support during the stimulation cycle, removing the main concern about the shorter LH surge. This strategy has already been validated with GnRH agonist trigger and could be even more effective with kisspeptin. The peptide signaling involved here parallels other reproductive peptide cascades, as explored in how GnRH analogs restore testosterone.
Limitations of the Current Evidence
Several caveats apply to the kisspeptin IVF data.
Small sample sizes. The phase 2 trials enrolled 60-62 women each. While OHSS prevention was convincingly demonstrated, pregnancy rate comparisons are underpowered at these sample sizes. Phase 3 trials with hundreds of participants are needed before kisspeptin can be recommended over established triggers.
High-risk populations only. The trials specifically enrolled women at high risk of OHSS (high antral follicle counts, elevated AMH, high estradiol during stimulation). Whether kisspeptin offers advantages in normal-risk populations, where OHSS is already rare, is unknown.
Single-center data. Most kisspeptin IVF data comes from Hammersmith Hospital/Imperial College London. Multi-center replication is needed to confirm these results across different clinic protocols and patient populations.
Luteal phase support. Like GnRH agonist trigger, kisspeptin trigger produces a shorter LH surge that may compromise the luteal phase. Optimal luteal support protocols for kisspeptin trigger have not been standardized.
No direct kisspeptin product. Kisspeptin-54 is not commercially available as a pharmaceutical product. Clinical use would require development of a licensed formulation with standardized dosing, stability, and administration guidelines. The peptide's short half-life (approximately 28 minutes for kisspeptin-54) means the dosing window is narrow and must be precisely timed relative to planned egg retrieval. Longer-acting kisspeptin analogs have been proposed but none have entered clinical development for IVF.
Unknown interactions with stimulation protocols. Current IVF protocols use various combinations of FSH, LH, and GnRH antagonists during the stimulation phase. Whether kisspeptin trigger efficacy varies by stimulation protocol, gonadotropin brand, or GnRH antagonist type has not been systematically studied. The phase 2 trials used specific protocols that may not generalize to all clinical settings.
For a related perspective on fertility biomarkers, see AMH: the peptide biomarker for fertility. For more on the reproductive peptide cascade, see peptide hormones and follicle development and kisspeptin and ovulation as an IVF trigger alternative.
The Bottom Line
Kisspeptin-54 triggers oocyte maturation during IVF by stimulating the brain's own GnRH-LH cascade rather than directly stimulating the ovaries. Phase 2 trials in high-risk women demonstrated 95% oocyte maturation with zero OHSS cases, and head-to-head comparisons showed dramatically lower ovarian volumes and symptom rates than both hCG and GnRH agonist triggers. The evidence is promising but limited to small, single-center phase 2 studies. Phase 3 trials are needed to establish kisspeptin's place alongside established IVF triggers.